Summary The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium
(CPTAC) investigates tumors from a proteogenomic perspective, creating rich multi-omics …

Genomic analyses in cancer have been enormously impactful, leading to the identification of
driver mutations and development of targeted therapies. But the functions of the vast majority …

Mass-spectrometry-based proteomic data on human tumors—combined with corresponding
multi-omics data—present opportunities for systematic and pan-cancer proteogenomic …

Abstract Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-
negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which …

MYC-driven medulloblastomas (MB) are highly aggressive pediatric brain tumors with poor
outcomes, and effective therapies remain limited despite intensive multimodal treatments …

Inflammatory bowel disease (IBD) is an immune-mediated disease of the intestinal tract, with
complex pathophysiology involving genetic, environmental, microbiome, immunological and …

Pediatric tumors are uncommon, yet are the leading cause of cancer-related death in
childhood. Tumor types, molecular characteristics, and pathogenesis are unique, often …

Clear cell renal cell carcinoma (ccRCC) is a common and aggressive subtype of renal
cancer. Here we conduct a comprehensive proteogenomic analysis of 232 tumor and …

When it comes to precision oncology, proteogenomics may provide better prospects to the
clinical characterization of tumors, help make a more accurate diagnosis of cancer, and …

Soft tissue sarcomas (STS) are rare and diverse mesenchymal cancers with limited
treatment options. Here we undertake comprehensive proteomic profiling of tumour …